Oral Semaglutide
Novo Nordisk’s Rybelsus® is now the first oral GLP-1 RA approved in Europe with cardiovascular benefit, following positive SOUL trial results. This milestone reshapes the GLP-1 landscape, combining oral convenience with outcomes data, and may accelerate adoption in China’s type 2 diabetes market.
AI Co-Scientist
Explore how large language models (LLMs) and AI co-scientists are revolutionizing hypothesis generation in molecular biology. Insights from recent Cell studies on cf-PICIs reveal AI’s potential to complement experimental research.
AI Co-Scientist
通过大语言模型和多智能体推理，AI Co-Scientist成功重现cf-PICIs的跨物种机制，凸显AI在分子微生物学中辅助假说生成与研究设计的潜力。
Sino–American Shanghai Squibb
Sino–American Shanghai Squibb, established in 1982, was China's first Sino–U.S. pharmaceutical joint venture. This report delves into its legacy, challenges faced, and the anticipated transition under Hillhouse Capital.
中美上海斯贵宝
中美上海斯贵宝成立于1982年，是中国首家中美合资制药企业。本文深入分析其历史遗产、面临的挑战以及预计在高瓴资本领导下的转型。
HPV vaccine China
China’s HPV vaccine market is transforming in 2025, with NIP rollout, price wars among domestic manufacturers, and potential gains in cervical cancer prevention.
医药产业
2025年全球制药业迎来产业快速转折：默沙东、礼来、阿斯利康在英国战略收缩，减肥药之王诺和诺德全球大幅裁员；中国创新药企恒瑞、三生制药等纷纷授权出海，与国际药企合作，重塑全球医药创新格局。
Pharma Industry
Merck’s UK exits, AstraZeneca’s paused investment, Lilly’s stalled Gateway Labs project, Novo Nordisk’s workforce cuts, and China’s record out-licensing deals with Hengrui and Pfizer/3SBio mark a turning point for the global pharmaceutical industry in 2025.
Baili Pharma
Baili Pharma has launched a head-to-head Phase III trial of BL-M07D1 versus Keytruda + chemo in first-line HER2-mutant NSCLC, a bold challenge to the current standard. Baili is also advancing Iza-Bren, an EGFR/HER3 ADC with strong Phase II results.
Maze Therapeutics
Maze Therapeutics’ SLC6A19 inhibitor MZE782 showed >40-fold phenylalanine excretion in Phase 1, advancing toward Phase 2 trials in PKU and CKD. The data position MZE782 as a potential best-in-class therapy for PKU and first-in-class option for CKD, directly challenging Jnana’s JNT-517.
KN026
China’s NMPA has accepted the NDA for Alphamab/CSPC’s KN026 (anbenitamab), the first domestic HER2 bispecific antibody to reach filing in gastric cancer. Backed by the KC-WISE Phase II/III trial, the drug could address a major gap in second-line HER2-positive gastric/GEJ adenocarcinoma.
daraxonrasib
Revolution Medicines unveiled updated clinical results for daraxonrasib in metastatic pancreatic cancer. Early Phase 1 data reveal 47% ORR as monotherapy and 55% in combination with chemotherapy, supporting a pivotal RASolute 303 phase 3 trial in first-line metastatic disease.